<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37316681</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Tofersen: First Approval.</ArticleTitle><Pagination><StartPage>1039</StartPage><EndPage>1043</EndPage><MedlinePgn>1039-1043</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-023-01904-6</ELocationID><Abstract><AbstractText>Tofersen (Qalsody<sup>&#x2122;</sup>) is an antisense oligonucleotide being developed by Biogen for the treatment of amyotrophic lateral sclerosis (ALS). On 25 April 2023, tofersen was approved in the USA for the treatment of ALS in adults who have a mutation in the superoxide dismutase&#xa0;1 (SOD1) gene. This article summarizes the milestones in the development of tofersen leading to this first approval for ALS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Hannah A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2NU6F9601K</RegistryNumber><NameOfSubstance UI="C000709090">tofersen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37316681</ArticleId><ArticleId IdType="doi">10.1007/s40265-023-01904-6</ArticleId><ArticleId IdType="pii">10.1007/s40265-023-01904-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen JJ. Overview of current and emerging therapies for amytrophic lateral sclerosis. Am J Manag Care. 2020;26(9 Suppl):S191&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead RJ, Shan N, Reiser HJ, et al. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22(3):185&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00612-2</ArticleId><ArticleId IdType="pubmed">36543887</ArticleId></ArticleIdList></Reference><Reference><Citation>de Courssou J-BB, Durr A, Adams D, et al. Antisense therapies in neurological diseases. Brain. 2022;145(3):816&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab423</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen MA Inc. QALSODY (tofersen) injection, for intrathecal use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887s000lbl.pdf . Accessed 30 May 2023.</Citation></Reference><Reference><Citation>Biogen IP. Biogen exercises option with Ionis to develop and commercialize investigational treatment BIIB067 for a subtype of familial amyotrophic lateral sclerosis (ALS) based on positive phase 1 data [media release]. 6 Dec 2018. http://www.biogen.com .</Citation></Reference><Reference><Citation>Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Investig. 2006;116(8):2290&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId><ArticleId IdType="pmc">1518790</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId><ArticleId IdType="pmc">3712285</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Shaw PJ, et al. Safety, PK, PD, and exploratory efficacy in a single and multiple-dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS [abstract no. 6.077 plus poster]. Neurology. 2019;93(5):E533.</Citation></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Glass JD, Cudkowicz M, et al. Statistical model of the relationship of neurofilament with clinical function in the VALOR phase 3 study of tofersen in adults with SOD1-ALS [abstract no. 32]. Muscle Nerve. 2022;66(S2):S16.</Citation></Reference><Reference><Citation>Miller TM, Cudkowicz M, Genge A, et al. Evaluating efficacy and safety of tofersen in adults with SOD1-ALS: results from the phase 3 VALOR trial and open-label extension [abstract no. C05]. In: 33rd International Symposium on ALS/MND. 2022.</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics. 2022;19(4):1248&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId><ArticleId IdType="pmc">9587202</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food &amp; Drug Administration. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene [media release]. 25 Apr 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>